确定在患有罕见癌症的患者中实施精确瘤学的障碍
Shigemasa Takamizawa1, Takafumi Koyama1, Kuniko Sunami2
1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Cancer science
|March 27, 2024
概括
在罕见的癌症中,综合基因组分析 (CGP) 显示由于很少有针对性的药物,其效用有限. 将CGP专注于现有基于证据的治疗选择的患者,可以最大限度地提高其在精密瘤学中的价值.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 翻译医学是一种翻译医学.
背景情况:
- 由于患者人数较少,罕见癌症存在治疗挑战.
- 综合基因组分析 (CGP) 可能无法在罕见癌症中充分利用精确瘤学.
研究的目的:
- 探索影响罕见癌症中CGP实用性的因素.
- 为了确定实施精确瘤学对罕见癌症患者的障碍.
主要方法:
- 2019年9月至2021年6月期间接受CGP的患者的回顾性研究.
- 单变量和多变量分析,以评估患者特征与接受分子向药物之间的关联.
- 对基因组变化的评估和随后的向或免疫检查点抑制剂疗法.
主要成果:
- 在333名罕见癌症患者中,83.5%有可采取行动的基因组变化,38.1%有可药物治疗的基因组变化.
- 只有7.5%的人接受了基因组匹配疗法.
- 有基于证据的治疗选择 (A-D) 的患者比没有 (2,9%) 的患者更频繁地 (8.7%) 接受向药物治疗.
结论:
- 对向药物的有限临床证据是CGP在罕见癌症中的实用性的障碍.
- 在现有基于证据的治疗选择 (A-D) 的罕见癌症患者中进行CGP可以增强其现实世界的应用.
- 优化CGP的使用对于在罕见恶性瘤中推进精密瘤学至关重要.
更多相关视频
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.8K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.0K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
